Page last updated: 2024-12-11

zanoterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9844827
CHEMBL ID1908363
CHEBI ID188685
SCHEMBL ID60980
MeSH IDM0168039

Synonyms (22)

Synonym
107000-34-0
D06357
zanoterone (usan/inn)
zanoterone
(1s,2s,10s,13r,14s,17r,18s)-17-ethynyl-2,18-dimethyl-6-methylsulonyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4,7-dien-17-ol
CHEBI:188685
xq5v1w49jg ,
win 49,596
unii-xq5v1w49jg
zanoterone [usan:inn]
1'h-pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)-
1'-(methylsulfonyl)-1'h-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol
bdbm50368314
win-49596
CHEMBL1908363
zanoterone [usan]
zanoterone [inn]
SCHEMBL60980
DTXSID50147873
win49596
Q15633966
(1s,2s,10s,13r,14s,17r,18s)-17-ethynyl-2,18-dimethyl-6-methylsulfonyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4,7-dien-17-ol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The effects of Win 49,596 at a dosage of 40 mg/kg/day were similar to that observed for the nonsteroidal androgen receptor antagonist flutamide at 10 mg/kg/day."( Effect of the steroidal androgen receptor antagonist Win 49,596 on steroid-induced benign prostatic hyperplasia in the castrate beagle dog.
Barbolt, TA; Batzold, FH; Juniewicz, PE; LaBrie, TK; Lemp, BM; McCarthy, M; Reel, JR, 1990
)
0.28
" In the last experiment, at equivalent total daily dosages of either 150 or 300 mg/kg/day Win 49,596, twice a day (BID) dosing was more effective than once a day (SID) dosing in inhibiting tumor growth."( Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer.
Fetrow, N; Isaacs, JT; Juniewicz, PE; Lamb, J; Marinelli, J; Wolf, M; Young, E, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID176392Antiandrogenic activity as the dose required to inhibit testosterone propionate-induced rat ventral prostate weight gain in castrated immature rat by 50%.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID39173Effective dose required for the compound to inhibit testosterone propionate-stimulated prostate weight gain by 50% using [3H]- R1881 as the radioligand1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Androgen receptor affinity of 5'-acyl furanosteroids.
AID176903Peroral dose inhibiting testosterone propionate (subcutaneous administration) induced rat ventral prostate weight gain by 50%1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles.
AID39323Relative binding affinity against rat ventral prostate androgen receptor using competition assay after 18 hours.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID39298Relative binding affinity (RBA) towards androgen receptor in rat ventral prostate cytosol, following 18 hr incubation time period1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Androgen receptor affinity of 5'-acyl furanosteroids.
AID39322Relative binding affinity against rat ventral prostate androgen receptor using competition assay after 1 hour.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID183961Androgenic activity as percent increase in rat ventral prostate (castrated immature rat) weight caused by 100 mg/kg per day x 10 oral dose; Not significant1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
Antiandrogenic steroidal sulfonylpyrazoles.
AID39297Relative binding affinity (RBA) towards androgen receptor in rat ventral prostate cytosol, following 1 hr incubation time period1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Androgen receptor affinity of 5'-acyl furanosteroids.
AID39294In vivo binding affinity for rat ventral prostate androgen receptor by displacement of [3H]R-18811992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles.
AID230354In vivo relative binding affinity (1h/18h) as ratio of binding affinities for R1881 and compound against rat ventral prostate androgen receptor using [3H]- R1881 as radioligand; 2.2/0.051992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (15.79)18.7374
1990's16 (84.21)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.98 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.26%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]